News
11-16-2010, 10:20 PM
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
More... (http://www.news-medical.net/news/20101117/AVEO-commences-enrollment-in-Phase-1b-combination-trial-of-tivozanib-with-oral-capecitabine-in-advanced-tumors.aspx)
More... (http://www.news-medical.net/news/20101117/AVEO-commences-enrollment-in-Phase-1b-combination-trial-of-tivozanib-with-oral-capecitabine-in-advanced-tumors.aspx)